LSA
BBIO icon

L & S Advisors’s BridgeBio Pharma BBIO Stock Holding History

L & S Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Sell
16,249
-5,962
-27% -$432K 0.15% 134
2025
Q4 		$1.7M Buy
22,211
+5,318
+31% +$349K 0.16% 160
2025
Q3 		$877K Buy
+16,893
New +$824K 0.08% 179

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

L & S Advisors's BBIO Position: Q1 2026 in Review

L & S Advisors reduced its BridgeBio Pharma (BBIO) stake by 27% in Q1 2026, selling an estimated $432K and leaving 16,249 shares worth $1.21M. The position accounts for 0.15% of the portfolio, ranked #134.

L & S Advisors first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.7M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • L & S Advisors held 16,249 shares of BridgeBio Pharma worth $1.21M as of Q1 2026.
  • L & S Advisors sold 5,962 BridgeBio Pharma shares in Q1 2026, an estimated $432K.
  • BridgeBio Pharma made up 0.15% of L & S Advisors's portfolio in Q1 2026, its #134 holding.
  • L & S Advisors first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • L & S Advisors's BridgeBio Pharma position peaked at $1.7M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on L & S Advisors's 13F filing for Q1 2026, filed 11 May 2026.